bumetanide · Corstasis Therap · NDA 219500
Enbumyst
Earliest generic entry, as listed
14 May 2045
Blocked by patent: US 12558330.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12558330 | drug product, use U-4279 · sets the listed date | 14 May 2045 |
| US 11123319 | drug product | 4 Dec 2040 |
| US 11260038 | use U-4279 | 4 Dec 2040 |
| US 12329731 | drug product, use U-4279 | 4 Dec 2040 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219500 · 001 · RLD | spray, nasal | 0.5MG/SPRAY | 14 May 2045 |